Ther4 is an ApoA-I fusion protein providing the main protein associated with HDL
ApoA-I typically has short half-life in the lipid-free state, whereas Ther4 has a longer half-life
One indication is to improve reverse cholesterol transport with potential to stabilize and/or reduce coronary plaques
ApoA-I can also neutralize LPS which is the endotoxin that drives gram-negative sepsis
A second indication is to reduce the endotoxemia burden of sepsis which can reduce sepsis-associated kidney failure and other complications leading to decreased ICU stay, morbidity and mortality
ApoA-I is a powerful anti-inflammatory molecule typically associated with its actions with or without HDL.
A third indication is utility in autoimmune disease to improve and resolve inflammation in diseases like inflammatory bowel disease, rheumatoid arthritis and others.
TR-43
PON1 Fc molecule providing the antioxidant enzyme paraoxonase 1
This is a first-in-class molecule providing a long half-life to this important enzyme
The enzyme is deficient in many diseases including fibrosis and inflammation
There is also potential of this enzyme to provide protection from harmful chemicals such as pesticides and chemical nerve agents
Recent literature suggests a potential use as a tumor “metabolic” checkpoint inhibitor that can reduce tumor burden in hepatocellular carcinoma either alone or synergistically with immune checkpoint inhibitors
There are promising data regarding prevention of diabetes in a rodent model of type 1 diabetes and treatment of insulin resistance in a different rodent model using recombinant PON 1
Paraoxonase Fusion Protein Platform
Bispecific molecules combined with the antioxidant enzyme paraoxonase 1
This is a first-in-class platform providing combination therapies for a multitude of diseases including heart disease and inflammatory conditions
US patent issued 12/31/24 covering Theripion bifunctional PON1 molecules
